Classys New Product 'Shurink Universe' Surpasses 1,000 Units Sold Globally
[Asia Economy Reporter Lee Gwan-joo] Classys announced on the 8th that the global cumulative sales of its skin lifting device Shrink's new product 'Shrink Universe' (overseas name Ultraformer MPT) have surpassed 1,000 units.
Shrink Universe recorded sales of 200 units within one month of its release after receiving medical device approval from the Ministry of Food and Drug Safety in October last year. Since then, it achieved a record quarterly sales of 35.4 billion KRW in the first quarter, and the current cumulative domestic sales have exceeded 900 units. Exports are expected to expand through country-specific approvals starting with Japan overseas.
Shrink Universe received particularly positive responses from clinics highly satisfied with the existing Shrink. Upgraded from the existing Shrink, it allows the use of two strong ultrasound energy modes, MP and Normal (Dot), with a single button. Additionally, it can be applied to necessary areas using seven different cartridges.
Hot Picks Today
SpaceX Opens IPO Floodgates... Anthropic and OpenAI Push Valuations into the Trillions
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "From 119 Call to Hospital Transport"... Saving Sudden Cardiac Arrest Patients with AI and Video Calls
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
A Classys official stated, "As the cumulative sales of Shrink exceeded 3,500 units as of last year, we will also increase the sales volume of Shrink Universe," adding, "We will focus on expanding the global market by obtaining approval for Shrink Universe in more than 60 countries where we are currently operating."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.